Study Shows Senetek PLC's Invicorp Well-Tolerated as Treatment for Erectile Dysfunction in Men With High Blood Pressure

Apr 20, 2001, 01:00 ET from Senetek PLC

    NAPA, Calif., April 20 /PRNewswire Interactive News Release/ --
 Senetek PLC (Nasdaq:   SNTKY), http://www.senetekplc.com , which develops
 products in two key markets, anti-aging and sexual dysfunction, today
 announced that a study conducted in Europe shows its erectile dysfunction
 product, Invicorp(TM), is well-tolerated in patients suffering from
 hypertension, commonly known as high blood pressure.
     Dr. Wallace Dinsmore, Belfast, North Ireland, studied 21 patients with
 erectile dysfunction and a history of hypertension, which is common in men
 with ED.  The double blind, placebo controlled study, designed to evaluate
 Invicorp's tolerance in ED patients with hypertension, included comprehensive
 measurement of significant variables including systolic blood pressure,
 diastolic blood pressure, mean arterial pressure, and pulse rates.  Study
 results demonstrated Invicorp was well-tolerated by these patients and is
 well-suited for use in this population.  Dr. Dinsmore said this analysis is
 consistent with previously observed results.  More than one in four adults are
 believed to have high blood pressure.
     "Invicorp is a therapy of great promise compared to existing oral,
 intracavernous and other therapies from the standpoint of both safety and
 efficacy," Dr. Dinsmore said.  He also stated that his research with Invicorp
 shows it is particularly useful for patients with hypertension.  Dr. Dinsmore
 was involved in the early European studies of Viagra, an oral treatment for
 ED, and is the Secretary of the British Society for Sexual and Impotence
 Research.
     Decision Resources, Inc., in a major report of the potential treatments
 for ED, said ED in men with hypertension is frequently related to the drugs
 they take for treatment, although it said withdrawal of the drug does not
 necessarily restore erectile function.  It praised Senetek's product for its
 rapid onset of action, within two to five minutes, and its safety profile.
 "Physicians are enthusiastic about Senetek's new combination injection
 therapy, which uses vasoactive intestinal polypeptide and phentolamine
 mesylate," the report said.  "We believe it could become the injection therapy
 of choice."  Decision Resources has been a world leader in research in
 pharmaceuticals and the health care industry worldwide for more than 30 years.
     "The work by Dr. Dinsmore further reaffirms the advantages that Invicorp
 possesses as a highly effective treatment for patients with moderate to severe
 erectile dysfunction, including populations of ED patients who have failed
 other therapies or who cannot tolerate currently available therapies because
 of their underlying medical conditions.  Millions of men worldwide suffer from
 ED and we are confident that Invicorp will play an important role in treating
 a portion of this population," said Frank J. Massino, Chairman and CEO.
     Senetek PLC, headquartered in Napa, Ca., http://www.senetekplc.com , is a
 science-driven biopharmaceutical company engaged in the development of
 products for anti-aging and sexual dysfunction.
 
     This press release and Website may contain certain forward-looking
 statements.  Actual events or results may differ from the Company's
 expectations as a result of a number of factors, including those set forth in
 Senetek's Annual Report, its Form 10K and subsequent regulatory filings.
 There can be no assurance that any product in Senetek's product pipeline will
 be successfully developed or manufactured, or that final results of human
 pilot studies or clinical studies will be supportive of regulatory approvals
 required to market products.
 
     CONTACT:  Investor Relations of Senetek PLC, 707-226-3900 ext. 102, or
 Pknopick@eandecommunications.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48234611
 
 

SOURCE Senetek PLC
    NAPA, Calif., April 20 /PRNewswire Interactive News Release/ --
 Senetek PLC (Nasdaq:   SNTKY), http://www.senetekplc.com , which develops
 products in two key markets, anti-aging and sexual dysfunction, today
 announced that a study conducted in Europe shows its erectile dysfunction
 product, Invicorp(TM), is well-tolerated in patients suffering from
 hypertension, commonly known as high blood pressure.
     Dr. Wallace Dinsmore, Belfast, North Ireland, studied 21 patients with
 erectile dysfunction and a history of hypertension, which is common in men
 with ED.  The double blind, placebo controlled study, designed to evaluate
 Invicorp's tolerance in ED patients with hypertension, included comprehensive
 measurement of significant variables including systolic blood pressure,
 diastolic blood pressure, mean arterial pressure, and pulse rates.  Study
 results demonstrated Invicorp was well-tolerated by these patients and is
 well-suited for use in this population.  Dr. Dinsmore said this analysis is
 consistent with previously observed results.  More than one in four adults are
 believed to have high blood pressure.
     "Invicorp is a therapy of great promise compared to existing oral,
 intracavernous and other therapies from the standpoint of both safety and
 efficacy," Dr. Dinsmore said.  He also stated that his research with Invicorp
 shows it is particularly useful for patients with hypertension.  Dr. Dinsmore
 was involved in the early European studies of Viagra, an oral treatment for
 ED, and is the Secretary of the British Society for Sexual and Impotence
 Research.
     Decision Resources, Inc., in a major report of the potential treatments
 for ED, said ED in men with hypertension is frequently related to the drugs
 they take for treatment, although it said withdrawal of the drug does not
 necessarily restore erectile function.  It praised Senetek's product for its
 rapid onset of action, within two to five minutes, and its safety profile.
 "Physicians are enthusiastic about Senetek's new combination injection
 therapy, which uses vasoactive intestinal polypeptide and phentolamine
 mesylate," the report said.  "We believe it could become the injection therapy
 of choice."  Decision Resources has been a world leader in research in
 pharmaceuticals and the health care industry worldwide for more than 30 years.
     "The work by Dr. Dinsmore further reaffirms the advantages that Invicorp
 possesses as a highly effective treatment for patients with moderate to severe
 erectile dysfunction, including populations of ED patients who have failed
 other therapies or who cannot tolerate currently available therapies because
 of their underlying medical conditions.  Millions of men worldwide suffer from
 ED and we are confident that Invicorp will play an important role in treating
 a portion of this population," said Frank J. Massino, Chairman and CEO.
     Senetek PLC, headquartered in Napa, Ca., http://www.senetekplc.com , is a
 science-driven biopharmaceutical company engaged in the development of
 products for anti-aging and sexual dysfunction.
 
     This press release and Website may contain certain forward-looking
 statements.  Actual events or results may differ from the Company's
 expectations as a result of a number of factors, including those set forth in
 Senetek's Annual Report, its Form 10K and subsequent regulatory filings.
 There can be no assurance that any product in Senetek's product pipeline will
 be successfully developed or manufactured, or that final results of human
 pilot studies or clinical studies will be supportive of regulatory approvals
 required to market products.
 
     CONTACT:  Investor Relations of Senetek PLC, 707-226-3900 ext. 102, or
 Pknopick@eandecommunications.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48234611
 
 SOURCE  Senetek PLC

RELATED LINKS

http://www.senetekplc.com